Enveric Biosciences ENVB Institutional Ownership

Ownership Summary

Enveric Biosciences, Inc. (NASDAQ:ENVB) showed up in the 13F filings of 11 institutional investors as of March 2026.

• They owned 3.6% of outstanding stock in March 2026, down from 7.2% the prior quarter.
• They increased total shares held in Enveric Biosciences by 151.17% from the prior quarter, while the number of investors in ENVB decreased 31.25% year over year.
• Among the 11 funds, 5 bought more Enveric Biosciences shares, 1 sold down, and 5 held their ground.
• Combined, these investors held 54.98K shares in ENVB for March 2026, up by 33.09K shares quarter on quarter, and up 33.87K shares year over year.
• GEODE CAPITAL MANAGEMENT, LLC holds the largest position in ENVB at 32.15K shares as of March 31, 2026, or 2.13% of shares outstanding.
• The largest buyers of Enveric Biosciences for the quarter ending March 2026 were GEODE CAPITAL MANAGEMENT, LLC (32.15K), JONES FINANCIAL COMPANIES LLLP (1.0K), UBS Group AG (717), SBI Securities Co., Ltd. (34), DANSKE BANK A/S (1).
• Top sellers of ENVB stock for the quarter ending March 2026 included Tower Research Capital LLC (TRC) (814).
• Business Quant data shows the 10 biggest positions in Enveric Biosciences as of March 2026 are held by GEODE CAPITAL MANAGEMENT, LLC (32.15K), AdvisorShares Investments LLC (16.97K), UBS Group AG (3.61K), Tower Research Capital LLC (TRC) (1.1K), JONES FINANCIAL COMPANIES LLLP (1.0K), SBI Securities Co., Ltd. (83), BlackRock, Inc. (51), NATIONAL BANK OF CANADA /FI/ (1), DANSKE BANK A/S (1), Wells Fargo & Company/Mn (1).